Clinical Trial Update: A Phase 1/2a Study to Determine the Dose Response Pharmacokinetics of TSX-011 (Testosterone Undecanoate) in Hypogonadal Males [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2a trial evaluating dose response pharmacokinetics of TSX-011 (testosterone undecanoate) in hypogonadal males was terminated, with results posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endocrine System Diseases
• Gonadal Disorders
• Hypogonadism
• Testosterone Deficiency

Drugs mentioned

• TSX-011 (testosterone undecanoate)

Snippet

Sponsor: TesoRx Pharma, LLC | Conditions: Hypogonadism, Hypogonadism, Male | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2019-05-16